Phase 2 SCOPE Trial of SCIB1 Achieves Positive ORR in Advanced Melanoma
Source: Targeted Oncology, September 2023
Positive objective response results were demonstrated in the first stage of the phase 2 SCOPE trial. Now, 27 additional patients with advanced melanoma will be treated with SCIB1 and checkpoint inhibitors in stage 2.
In patients with advanced melanoma treated with SCIB1 in combination with checkpoint inhibitors (CPIs), there was an 82% objective response rate (ORR) to treatment, according to initial data from the first stage in the phase 2 SCOPE trial (NCT04079166).
To date, 11 of 16 study patients have reached 13 weeks and been evaluated at radiological imaging. Nine of these patients have already shown an objective response with no increase in toxicity. These data were better than the 70% ORR that the trial was configured to show, and better than the 50% ORR seen in patients treated with the current standard-of-care alone.